The clinical activity of VenclextaTM in these BCL-2 overexpressing hematological malignancies and its recent approval for patients with relapsed or refractory CLL with 17p deletion provide very strong clinical proof-of-concept and seminal registration for drugs targeting the BCL-2 family. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.